NTGN Neon Therapeutics

About NTGN

BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
50

Neutral Sentiment

How do you feel about NTGN?

Advertisement|Remove ads.